ICMJE DISCLOSURE FORM

Dat	e : 10. november 2024					
Your Name:		Thomas Benfield				
Manuscript Title:		Click or tap here to enter text.				
Manuscript Number (if known):						
are r third comi	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that re related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit hird parties whose interests may be affected by the content of the manuscript. Disclosure represents a ommitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to st a relationship/activity/interest, it is preferable that you do so.					
	uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>			
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.						
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
Tim	e frame: Since the initial plan	•				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None				
	No time limit for this					
	item.					
			Click TAB in last row to add extra rows			
Tim	e frame: past 36 months					
2						
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None Novo Nordisk Foundation	Unrestricted grant to my institution			
		Simonsen Foundation	Unrestricted grant to my institution			
		GSK	Unrestricted grant to my institution, principal investigator // clinical trial, and advisory board			

	1		
		Pfizer	Unrestricted grant to my institution, principal
			investigator//clinical trial, advisory board
		Gilead Sciences	Unrestricted grant to my institution, principal investigator//clinical trial, advisory board
		MSD	Unrestricted grant to my institution, principal
			investigator, advisory board
		Segirus UK Limited	principal investigator // clinical trial
		Janssen	Advisory board, principal investigator // clinical trial
		Astra Zeneca	Advisory board, principal investigator // clinical trial
		Moderna Tx	Advisory board, principal investigator // clinical trial
		Sanofi	principal investigator // clinical trial
		STRIVE / INSIGHT / NIH	principal investigator // clinical trial
			principal mices garden, y amines, and
3 Royalties or licenses 🗵 None		⊠ None	
4	Consulting fees	□ None	
		GSK	
		Pfizer	
		MSD	
		Gilead	
		Janssen	
5	Payment or honoraria for	□ None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	GSK	lecture
		Pfizer	lecture
		Gilead Sciences	lecture
	educational events	Astra Zeneca	lecture
		Bavarian Nordic	lecture
6	Payment for expert	⊠ None	
	testimony		
7	Support for attending	□ None	
,	meetings and/or travel		
	meetings and or traver	MSD	
8	Patents planned, issued or	⊠ None	
	pending		
9	Participation on a Data	□ None	
	Safety Monitoring Board	COPERNICUS	EU CT: 2022-501035-16-01
	or Advisory Board	ORAL	NCT04140903, EU CT 2019-002845-39
	·		110104140000, 20 01 2010 002040-00
10	Leadership or fiduciary	⊠ None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	□ None	
	otock of stock options	- None	

		Novo Nordisk			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None			
13	Other financial or non- financial interests	⊠ None			

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.